The epidemiology of ocular and nasal allergy in the United States, 1988-1994

Singh, Kavita; Axelrod, Sara; Bielory, Leonard

doi:10.1016/j.jaci.2010.06.050

Cited by 235 publications

(169 citation statements)

References 12 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of allergic rhinoconjunctivitis and asthma in ASD-IS, ASD/FPIES, ASD/non-FPIES, as well as in non-ASD/FPIES children was found to be similar to what is reported in general population (Table 2) (Akinbami et al, 2011;Singh et al, 2010). However, ASD-IS children revealed a higher prevalence of recurrent infection [recurrent otitis media (ROM) and chronic rhinosinusitis (CRS)] than other study groups (Table 2).…”

Section: Clinical Featuressupporting

confidence: 80%

Impaired Oral Tolerance in ASD Children with Food Protein Induced Enterocolitis Syndrome (FPIES) – Altered Innate and Adaptive Immune Responses in ASD Children Recovered from FPIES in Comparison with non-ASD/FPIES and ASD/non-FPIES Children

Jyonouchi¹,

Geng²,

Kattouf³

et al. 2011

Autism - A Neurodevelopmental Journey From Genes to Behaviour

View full text Add to dashboard Cite

Section: Clinical Featuressupporting

confidence: 80%

Impaired Oral Tolerance in ASD Children with Food Protein Induced Enterocolitis Syndrome (FPIES) – Altered Innate and Adaptive Immune Responses in ASD Children Recovered from FPIES in Comparison with non-ASD/FPIES and ASD/non-FPIES Children

Jyonouchi¹,

Geng²,

Kattouf³

et al. 2011

Autism - A Neurodevelopmental Journey From Genes to Behaviour

View full text Add to dashboard Cite

“…For details to specific recommendations, see table 3. For details about local and systematic adverse reactions, see adverse event section above …”

Section: Clinicians Shouldmentioning

confidence: 99%

“…[3][4][5] It is associated with considerable loss of productivity and impaired school performance. 6 Allergic rhinoconjunctivitis can usually be diagnosed from its typical presentation ( Figure 1).…”

Section: Introductionmentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

561

705

View full text Add to dashboard Cite

drawn on data from a systematic review of the literature, more recent published studies and multistakeholder expert clinical opinion. This Guideline is aimed at healthcare professionals who are encouraged to take the recommendations into account in the context of delivering clinical care. This Guideline is not a substitute for professional clinical judgment, which professionals need to exercise in the context of delivering personalised healthcare. AbstractAllergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project "EAACI Guidelines on Allergen Immunotherapy." It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach.The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass 766 | ROBERTS, PFAAR ET AL. tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children. | ME TH ODOLOGYThis Guideline was produced using the Appraisal of Guidelines forResearch & Evaluation (AGREE II) approach, 17,18 a structured approach to guideline production (see Table S1). This is designed to ensure appropriate representation of the full range of stakeholders, a careful search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations and steps to ensure that the risk of bias is minimized at each step of the process. The process started on April 2015 beginning with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face meetings, and regular web conferences in which professional and lay representatives participated. | Clarifying the scope and purpose of the guidelinesThe scope of this EAACI Guideline is multifaceted...

show abstract

“…12,15 Majority of the patients (74.1%) in this study belonged to the 18-25 years age group and only 25.8% of the patients were above the age of 25 years. This was consistent with the studies done by John et al, and Abokyi et al, where the mean age of allergic conjunctivitis patients was about 20 years.…”

Section: Discussionmentioning

confidence: 79%

A prospective study of efficacy and safety of olopatadine versus azelastine in allergic conjunctivitis at a tertiary care hospital

Jayanthi

VIJAYALAKSHMI

2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

The principal symptom of Allergic Conjunctivitis is ocular itching. Other signs and symptoms include conjunctival redness, tearing, mucus discharge, chemosis and lid edema. Mast cells play an important role in the pathogenesis of Allergic Conjunctivitis. The binding of ABSTRACT Background: Allergic conjunctivitis, an ocular surface inflammatory disease with significant social and economic impact affects approximately 25% of the general population. H1 receptor blockers, mast cell stabilizers and drugs that block cytokine and prostaglandin formation form the treatment armamentarium. Olopatadine hydrochloride and Azelastine hydrochloride are dual-acting selective H1 receptor antagonist with mast-cell stabilizing property. This study was undertaken to assess the efficacy and safety of olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% in allergic conjunctivitis amongst Indians. Methods: After obtaining Institutional Ethics Committee approval and written informed consent, 120 patients diagnosed with allergic conjunctivitis fulfilling the inclusion/exclusion criteria were enrolled in the study. Study was done from April 2014 to June 2015 at Minto eye hospital. Study subjects were treated with olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% eye drops BD for 15 days. Ocular symptoms, instead of and signs and adverse events, if any were recorded on the day 8 and day 15 follow up visits. Results: At the end of the study period, the reduction in the ocular itching score from baseline was higher in the olopatadine group compared to the azelastine group (p<0.002). Similarly, the scores of ocular congestion (p<0.008), foreign body sensation (p<0.009), tearing (p<0.001), erythema (p<0.002) and chemosis (p<0.015) also showed larger reduction in the olopatadine treated patients. The common adverse events encountered in both the groups were stinging after instillation, burning, bitter taste and headache. Conclusions: In allergic conjunctivitis, both olopatadine and azelastine were found to be effective in relieving ocular signs and symptoms, but olopatadine was found to be superior in terms of efficacy, safety and tolerability with minimal side effects.

show abstract

The epidemiology of ocular and nasal allergy in the United States, 1988-1994

Cited by 235 publications

References 12 publications

Impaired Oral Tolerance in ASD Children with Food Protein Induced Enterocolitis Syndrome (FPIES) – Altered Innate and Adaptive Immune Responses in ASD Children Recovered from FPIES in Comparison with non-ASD/FPIES and ASD/non-FPIES Children

Impaired Oral Tolerance in ASD Children with Food Protein Induced Enterocolitis Syndrome (FPIES) – Altered Innate and Adaptive Immune Responses in ASD Children Recovered from FPIES in Comparison with non-ASD/FPIES and ASD/non-FPIES Children

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

A prospective study of efficacy and safety of olopatadine versus azelastine in allergic conjunctivitis at a tertiary care hospital

Contact Info

Product

Resources

About